ImmuCell Corporation (NASDAQ:ICCC - Get Free Report)'s share price crossed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $5.84 and traded as high as $6.53. ImmuCell shares last traded at $6.34, with a volume of 3,929 shares trading hands.
ImmuCell Stock Down 2.1%
The company has a debt-to-equity ratio of 0.28, a quick ratio of 1.99 and a current ratio of 3.85. The firm's 50-day simple moving average is $6.42 and its 200 day simple moving average is $5.88. The company has a market cap of $58.12 million, a P/E ratio of 33.82 and a beta of 0.29.
ImmuCell (NASDAQ:ICCC - Get Free Report) last released its quarterly earnings data on Thursday, August 14th. The biotechnology company reported $0.06 EPS for the quarter. ImmuCell had a net margin of 6.23% and a return on equity of 6.25%. The business had revenue of $6.45 million during the quarter.
Institutional Trading of ImmuCell
A number of large investors have recently made changes to their positions in the company. Geode Capital Management LLC increased its position in shares of ImmuCell by 4.2% in the 2nd quarter. Geode Capital Management LLC now owns 71,852 shares of the biotechnology company's stock valued at $500,000 after buying an additional 2,907 shares in the last quarter. Northern Trust Corp increased its holdings in ImmuCell by 51.0% during the 4th quarter. Northern Trust Corp now owns 44,374 shares of the biotechnology company's stock worth $229,000 after purchasing an additional 14,982 shares in the last quarter. Finally, Citadel Advisors LLC bought a new position in ImmuCell during the 4th quarter worth about $149,000. Institutional investors own 13.47% of the company's stock.
About ImmuCell
(
Get Free Report)
ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E.
See Also
Before you consider ImmuCell, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ImmuCell wasn't on the list.
While ImmuCell currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
